Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702).
OBJECTIVE
This prospective multicenter study aimed to evaluate the efficacy and safety of percutaneous radiofrequency (RF) ablation for lung cancer.


METHODS
From May 2008 to April 2012, 33 patients (26 men, 7 women; mean age 70.5 years) were enrolled. RF ablation was performed using an internally cooled or expandable multitined electrode. The primary endpoint was complete response (CR) determined using (18)F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) performed 6 months after RF ablation. The secondary endpoint was the incidence and grade of adverse events (AEs) evaluated using the Common Toxicity Criteria for Adverse Events, version 3.0.


RESULTS
All patients underwent RF ablation and had efficacy analyses evaluated; however, FDG-PET/CT images before RF ablation were not available for two patients. The CR rate was 68 % (21 of 31 patients). One patient had a grade 5 AE unrelated to RF ablation. Grade ≥3 AEs occurred in 12 % of patients. During the follow-up period (median 37 months; range 1-55 months), five patients developed local tumor progression and nine (29 %) died. Overall survival at 1, 2, and 3 years was 97, 82, and 74 %, respectively.


CONCLUSIONS
Percutaneous RF ablation is a safe, feasible, and effective treatment for small malignant lung tumors.
Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Japan. gobara@cc.okayama-u.ac.jp.
Hideo
H
Gobara
Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan.
Yasuaki
Y
Arai
Department of Interventional Radiology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Takeshi
T
Kobayashi
Department of Interventional Radiology, Mie University School of Medicine, Tsu, Japan.
Koichiro
K
Yamakado
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.
Yoshitaka
Y
Inaba
Department of Radiology, Teine Keijinkai Hospital, Sapporo, Japan.
Yoshihisa
Y
Kodama
Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takuji
T
Yamagami
Department of Radiology, Iwate Medical University School of Medicine, Morioka, Japan.
Miyuki
M
Sone
Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan.
Hirokazu
H
Watanabe
Department of Radiology, Fukuyama City Hospital, Fukuyama, Japan.
Yoshihiro
Y
Okumura
Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Japan.
Takayoshi
T
Shinya
Department of Diagnostic Radiology, National Cancer Center, Tokyo, Japan.
Hiroaki
H
Kurihara
Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Japan.
Susumu
S
Kanazawa
D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000601:surgery; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D000072078:Positron Emission Tomography Computed Tomography; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
Clinical trial; JIVROSG; Lung cancer; Multicenter; Prospective; Radiofrequency ablation